Researchers have spent decades chasing a Strep A vaccine and coming up empty; this month a UK regulator’s own lab published data showing a needle-free version works in mice, Healthcare Today reported.
The Medicines and Healthcare products Regulatory Agency, working with the GSK Vaccines Institute for Global Health, delivered a glycoconjugate vaccine via the nose and under the tongue and generated strong immune responses both at the mucosal surfaces where group A streptococcus takes hold and systemically throughout the body, according to the study published October 19 in Human Vaccines & Immunotherapeutics.
It is the first time a GMMA-based construct has been tested for mucosal delivery against Strep A, and the MHRA says the approach could yield an affordable vaccine that does not require cold-chain logistics or trained vaccinators.
“This research highlights the potential of GMMA technology to support a new generation of affordable, needle-free vaccines,” said Fatme Mawas, head of conjugate vaccines at the MHRA. “By delivering a Strep A vaccine through the nose or under the tongue, we showed that strong immune responses were generated both at the mucosal surfaces where infection begins and throughout the body, supporting protection against invasive disease.”
Strep A causes more than 600 million infections worldwide each year, and complications such as rheumatic heart disease and invasive disease kill over 500,000 people annually, the MHRA noted in its announcement on gov.uk. The burden falls hardest on low- and middle-income countries where antibiotic access is limited and follow-up care for rheumatic heart disease is often unavailable.
A mucosal vaccine that can be administered without needles would sidestep two of the biggest barriers in those settings: the need for sterile injection equipment and the cold chain required by most current vaccines.
The vaccine uses generalized modules for membrane antigens — tiny vesicles naturally shed by bacteria — as both a carrier for the Strep A carbohydrate antigen and an adjuvant to boost the immune response.
Unlike injectable candidates that mainly raise blood-borne antibodies, this formulation targets the nose and throat mucosa where the bacterium establishes infection, while still inducing systemic immunity. James Ozanne, Manolya Saydam, Elena Palmieri and eight co-authors from the MHRA and GSK Vaccines Institute for Global Health Srl detailed the preclinical mouse model in the paper, DOI 10.1080/21645515.2026.2740963.
MedicalXpress highlighted that the work forms part of the MHRA’s wider research program into vaccine science, immunology, assay development and novel delivery technologies. Clinical Services Journal added that the findings support further development of affordable, easily administered mucosal vaccines that could improve access to immunization worldwide and contribute to global efforts to reduce antimicrobial resistance by cutting the number of Strep A infections that trigger antibiotic prescriptions.
No licensed Strep A vaccine exists despite a century of effort; previous candidates have stumbled on safety signals, strain coverage gaps, and the commercial disincentive of a disease concentrated in poorer nations.
The GMMA platform is already being explored for other pathogens because it can be produced at low cost in standard bioreactors without complex purification. But the jump from immunogenic mice to a human product is long: the MHRA itself stresses the work is pre-clinical, and no timeline for first-in-human trials has been announced.
GSK plc emerged in 2000 from the merger of Glaxo Wellcome and SmithKline Beecham, creating a British pharmaceutical and biotechnology group headquartered in London. Its legacy includes the first malaria vaccine, RTS,S, pledged at five per cent above cost, and essential medicines such as amoxicillin and zidovudine.
The company’s Vaccines Institute for Global Health, which co-authored the Strep A study, operates from Siena, Italy, and focuses on diseases that disproportionately affect low-income countries.
The next step is clear but unfunded: toxicology studies, GMP manufacturing, and a phase 1 trial designed to measure mucosal IgA alongside serum IgG. Until a sponsor commits to that pipeline, the needle-free promise remains a promising mouse experiment — one that arrives just as global health agencies are renewing calls for a Strep A vaccine to curb the half-million annual deaths the bacterium still causes.